

Milada Zemanova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3307311/publications.pdf>

Version: 2024-02-01

59
papers

6,786
citations

393982

19
h-index

233125

45
g-index

59
all docs

59
docs citations

59
times ranked

9618
citing authors

#	ARTICLE	IF	CITATIONS
1	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2014, 383, 31-39.	6.3	1,833
2	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet, The</i> , 2013, 381, 805-816.	6.3	1,664
3	Durvalumab plus platinumâ€“etoposide versus platinumâ€“etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 394, 1929-1939.	6.3	1,274
4	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 59-68.	5.1	446
5	Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. <i>Lung Cancer</i> , 2004, 46, 87-98.	0.9	400
6	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.	0.8	316
7	Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. <i>Lung Cancer</i> , 2003, 41, 321-331.	0.9	153
8	Hormonal Regulation of Response to Oxidative Stress in Insectsâ€”An Update. <i>International Journal of Molecular Sciences</i> , 2015, 16, 25788-25816.	1.8	112
9	Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2020, 40, 2209-2217.	0.5	56
10	Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. <i>Diagnostic Pathology</i> , 2015, 10, 42.	0.9	47
11	Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. <i>European Urology</i> , 2016, 70, 469-475.	0.9	41
12	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.	0.9	39
13	Role of adipokinetic hormone and adenosine in the anti-stress response in <i>Drosophila melanogaster</i> . <i>Journal of Insect Physiology</i> , 2016, 91-92, 39-47.	0.9	36
14	Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 6771-6782.	0.5	33
15	MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. <i>Tumor Biology</i> , 2016, 37, 8007-8018.	0.8	31
16	Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 695-700.	1.1	31
17	Sorafenib Treatment of Advanced Renal Cell Carcinoma Patients in Daily Practice: The Large International PREDICT Study. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 156-164.e1.	0.9	30
18	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4507-4507.	0.8	28

#	ARTICLE	IF	CITATIONS
19	Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. <i>Ecological Management and Restoration</i> , 2010, 23, 160-167.	0.2	20
20	Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. <i>Oncologist</i> , 2020, 25, e598-e601.	1.9	18
21	Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. <i>Drugs and Aging</i> , 2016, 33, 655-663.	1.3	15
22	Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis. T.B. and B.M. received honoraria for advisory boards and lectures from Novartis and Pfizer. K.K. received honoraria for advisory boards and lectures from Novartis. Other authors have declared no conflict of interest. The RENIS registry is funded in part by pharmaceutical companies producing targeted agents for renal cancer (Pfizer, Bayer, GSK, Roche, and Novartis).. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 569-575.	0.8	12
23	Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. <i>European Journal of Cancer</i> , 2015, 51, 507-513.	1.3	12
24	The analysis of factors affecting the threshold on repeated 18F-FDG-PET/CT investigations measured by the PERCIST protocol in patients with esophageal carcinoma. <i>Nuclear Medicine Communications</i> , 2012, 33, 1188-1194.	0.5	11
25	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 259-270.	1.1	11
26	Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. <i>BMC Cancer</i> , 2017, 17, 880.	1.1	10
27	Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients. <i>Cancers</i> , 2020, 12, 808.	1.7	10
28	Serum Adiponectin Relates to Shortened Overall Survival in Men with Squamous Cell Esophageal Cancer Treated with Preoperative Concurrent Chemoradiotherapy: A Pilot Study. <i>Medical Science Monitor</i> , 2014, 20, 2351-2357.	0.5	10
29	Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 2807-2823.	0.0	10
30	Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry. <i>Cancers</i> , 2020, 12, 2911.	1.7	9
31	Plasma Phosphatidylcholines Fatty Acids in Men with Squamous Cell Esophageal Cancer: Chemoradiotherapy Improves Abnormal Profile. <i>Medical Science Monitor</i> , 2016, 22, 4092-4099.	0.5	8
32	Real-life effectiveness of first-line anticancer treatments in stage III/IV NSCLC patients: Data from the Czezech TULUNG Registry. <i>Thoracic Cancer</i> , 2020, 11, 3346-3356.	0.8	8
33	Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience. <i>Radiology and Oncology</i> , 2020, 54, 209-220.	0.6	8
34	FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal-gastric junction. <i>Abdominal Radiology</i> , 2016, 41, 2089-2094.	1.0	7
35	Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1047-e1053.	0.9	7
36	Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100427.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. <i>Anticancer Research</i> , 2018, 38, 449-456.	0.5	5
38	Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 294.e1-294.e8.	0.8	4
39	PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110651.	1.4	4
40	Treatment patterns and real-world evidence for stage III non-small cell lung cancer in Central and Eastern Europe. <i>Radiology and Oncology</i> , 2020, 54, 447-454.	0.6	3
41	Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy?. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 20-28.	2.2	2
42	Dendritic-cell vaccine (DCVAC) with first-line chemotherapy in patients with stage IV NSCLC: Final analysis of phase II, open label, randomized, multicenter trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9039-9039.	0.8	2
43	Peri-operative Chemotherapy in Patients with Oesophageal and Gastro-oesophageal Junction Cancer â€œ Three Years of Experience. <i>Prague Medical Report</i> , 2013, 114, 57-71.	0.4	2
44	Advances in radiotherapy for lung cancer. <i>Onkologie (Czech Republic)</i> , 2018, 12, 155-160.	0.0	2
45	Real-life Effectiveness of Afatinib <i>Versus</i> Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study. <i>Anticancer Research</i> , 2021, 41, 2059-2065.	0.5	1
46	Mammaglobin A, a novel marker of minimal residual disease in early stages breast cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 105.	2.2	0
47	P-978 Gefitinib (ZD 1839, IressaÂ®) in treatment of advanced non-small cell lung cancers â€œ one institutional experience on an expanded access program. <i>Lung Cancer</i> , 2005, 49, S377.	0.9	0
48	The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts). <i>Lung Cancer</i> , 2012, 77, S38.	0.9	0
49	Concurrent chemoradiotherapy in locally advanced non-small cell lung cancerâ€™ Prognostic factors and reasons for treatment failure in group of patients 1996â€™2008. <i>Lung Cancer</i> , 2012, 77, S42.	0.9	0
50	Prognostic role of early 18-FDG PET/CT during neoadjuvant chemotherapy for resectable adenocarcinoma of the esophagus and esophagogastric junction. <i>Neoplasma</i> , 2021, 68, 423-433.	0.7	0
51	Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment. <i>Anticancer Research</i> , 2021, 41, 2597-2603.	0.5	0
52	DETAILED DATA ANALYSIS OF CASE HISTORY, INCLUDING COINCIDENCE WITH COPD, SMOKING STATUS, AND RESECTABILITY IN LUNG CANCER PATIENTS IN THE PULMONARY DEPARTMENT, CHARLES UNIVERSITY, THE 1ST MEDICAL FACULTY IN PRAGUE, CZECH REPUBLIC. <i>Chest</i> , 2006, 130, 231S.	0.4	0
53	Three lines of targeted therapy for metastatic renal cell carcinoma (mRCC): A viable strategy?. <i>Journal of Clinical Oncology</i> , 2013, 31, e15581-e15581.	0.8	0
54	FDG-PET/CT in the prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15545-e15545.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC). , 2016, , .		0
56	Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic. , 2017, , .		0
57	Dendritic-cell vaccine (DCVAC) with first line chemotherapy in patients with stage IV NSCLC primary analysis of phase 2, open-label, randomized, multicenter trial.. Journal of Clinical Oncology, 2018, 36, 9051-9051.	0.8	0
58	Tyrosine-kinase inhibitors (TKI) in first-line treatment of patients with non-small cell lung cancer (NSCLC) - real life data from the Czech Republic. , 2018, , .		0
59	Real-life effectiveness of first-line treatments in NSCLC patients stage IIIB/IV“ data from the Czech TULUNG Registry. , 2020, , .		0